Kymera Therapeutics (NASDAQ: KYMR) reported Q4 EPS of ($0.88), $0.11 worse than the analyst estimate of ($0.77). Revenue for the quarter came in at $7.39 million versus the consensus estimate of $14.71 million.

For earnings history and earnings-related data on Kymera Therapeutics (KYMR) click here.